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Differential Effects of Polyphenols on Proliferation and Apoptosis in Human Myeloid 
and Lymphoid Leukemia Cell Lines 
Amani A Mahbub1, Christine L. Le Maitre1, Sarah L. Haywood-Small1, Gordon J. McDougall2,  
Neil A. Cross1 and Nicola Jordan-Mahy1,* 
1Biomedical Research Centre, Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, S1 1WB; 2The James Hutton 
Institute, Environmental and Biochemical Sciences Group, Invergowrie, Dundee Scotland, DD2 5DA 
Abstract: Background: Mortality rates for leukemia are high despite considerable improvements in treatment. Since polyphenols exert 
pro-apoptotic effects in solid tumors, our study investigated the effects of polyphenols in haematological malignancies. The effect of 
eight polyphenols (quercetin, chrysin, apigenin, emodin, aloe-emodin, rhein, cis-stilbene and trans-stilbene) were studied on cell 
proliferation, cell cycle and apoptosis in four lymphoid and four myeloid leukemic cells lines, together with normal haematopoietic 
control cells.  
Methods: Cellular proliferation was measured by CellTiter-Glo® luminescent assay; and cell cycle arrest was assessed using flow 
cytometry of propidium iodide stained cells. Apoptosis was investigated by caspase-3 activity assay using flow cytometry and apoptotic 
morphology was confirmed by Hoescht 33342 staining.  
Results: Emodin, quercetin, and cis-stilbene were the most effective polyphenols at decreasing cell viability (IC50 values of 5-22 ?M,  
8-33 ?M, and 25-85 ?M respectively) and inducing apoptosis (AP50 values (the concentration which 50% of cells undergo apoptosis) of 
2-27 ?M, 19-50 ?M, and 8-50 ?M respectively). Generally, lymphoid cell lines were more sensitive to polyphenol treatment compared to 
myeloid cell lines, however the most resistant myeloid (KG-1a and K562) cell lines were still found to respond to emodin and quercetin 
treatment at low micromolar levels. Non-tumor cells were less sensitive to all polyphenols compared to the leukemia cells.  
Conclusions: These findings suggest that polyphenols have anti-tumor activity against leukemia cells with differential effects. 
Importantly, the differential sensitivity of emodin, quercetin, and cis-stilbene between leukemia and normal cells suggests that 
polyphenols are potential therapeutic agents for leukemia. 
Keywords: Apoptosis, cell cycle, cell proliferation, leukemia, polyphenols. 
1. INTRODUCTION 
 Leukemia affects millions of people worldwide each year, 
resulting in almost one-third of all cancer deaths [1]. Leukemia is a 
complex disease affecting all blood cell lineages. Each 
classification is based, in part, on specific chromosomal and 
oncogenic rearrangements. Leukemia affects all age groups; it is the 
most common cancer in children and adolescents [1]. T- and B-cell 
lymphoblastic leukemia is the most common childhood disease [1, 
2], whilst Bcr-Abl-positive chronic myeloid leukemia (CML) is the 
most common in adults [1, 2]. The treatment regimens for leukemia 
will depend upon the leukemia type and the patient’s age and 
health. Treatments include chemotherapy, radiotherapy, immuno- 
therapy and bone marrow transplantation [1, 2]. Newer therapies 
also being used include tyrosine kinase inhibitors such as Imatinib, 
which specifically target the constitutively active tyrosine kinase 
domain of Bcr-Abl fusion gene present in the majority of chronic 
myeloid leukemia [3]. Despite considerable improvements in 
tolerance and efficacy of these treatments, the mortality rate of 
leukemia still remains high [1, 2]. Chemotherapies are by far the 
most commonly used treatments, however, many are expensive, 
mutagenic, carcinogenic or teratogenic [2]. Patients often experience 
considerable side effects, which are so severe that patients 
sometimes withdraw themselves from treatment, which results in 
poor prognosis [1, 2]. In addition, patients often fail to get complete 
disease remission, due to increased occurrence of drug resistance. It 
is for this reason, that it is important to find new treatments that can 
improve patient survival rates [1, 2]. 
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 These problems with current treatments have led to the search 
for new compounds for the treatment of leukemia. One area that has 
received great interest is the use of bio-active agents from natural 
sources [4-10]. Two groups of bioactive components that have 
shown potential are the polyphenols and polyacetylenes [4-10]. 
Epidemiological data has shown that diets rich in polyphenols 
significantly improve the quality of life and survival rates of 
patients with a range of chronic diseases, including cancer [11, 12]. 
Furthermore, these polyphenols are found naturally in a variety of 
foods and are well tolerated, with few side effects [11-13]. The 
selected polyphenols used in this study are representative of 3 
different classes of polyphenols, which have been previously shown 
to have anti-proliferative, pro-apoptotic and/or prevent the 
progression of solid tumors [9, 11-16] and a handful of leukemic 
cell lines, with the most commonly studied being the human 
promyleocytic: HL-60 cells [17-21]. The polyphenols investigated 
include the flavonol (quercetin), flavones (apigenin and chrysin), 
anthraquinones (emodin, aloe-emodin and rhein); and two stilbene 
isomers (cis-stilbene and trans-stilbene) (Table 1).  
 Previous work has demonstrated the pro-apoptotic and anti-
cancerous activity of polyphenols in a number of solid tumors  
[11-16] and a selection of leukemic cell lines [17-21]. However, 
there has not been a comprehensive comparison of the action of 
polyphenols within a wide range of leukemic cell lines. From 
previous studies, it is difficult to determine which polyphenols have 
the greatest potential for the treatment of leukemia. There are no 
direct comparisons of the IC50 values (the concentration which 
inhibits 50% of cell proliferation) or AP50 values (the concentration 
at which 50% of cells undergo apoptosis) for each polyphenol. 
Furthermore, it is unclear whether a single polyphenol is affective 
in all leukemia types; or whether specific polyphenols are only 
useful in single type or subset of leukemia. For this reason we 
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compared the anti-proliferative and pro-apoptotic effects of the 8 
polyphenols that have previously shown potential in solid and 
leukemic cell lines, on a panel of leukemic cell lines that represent 
the major leukemia types. These included four myeloid (KG-1a, 
HL-60, THP-1 and K562), three lymphoid (Jurkat, CCRF-CEM and 
MOLT-3) human leukemic cell lines and one histocytic lymphoma 
cell line (U937). In addition, for the first time we evaluated the 
action of these polyphenols on non-tumor hematopoietic stem 
progenitor cells (CD34+) from cord blood. 
 The aim of this study was to determine which polyphenols were 
the most effective at inhibiting cell proliferation and inducing 
apoptosis in each of the eight leukemic cell lines, whilst having a 
limited effect on the non-tumor cells. A direct comparison was 
made of the IC50 and AP50 values of each polyphenol in each cell 
line. Furthermore, we determined the action of each polyphenol on 
cell-cycle progression. 
2. MATERIALS AND METHODS 
2.1. Leukemia Cell Lines 
 Four myeloid human leukemia cell lines (HL-60 (Human 
promyelocytic leukemia) (ATCC: CCL-240, Middlesex, UK), THP-
1 (acute monocytic leukemia) (ATCC: TIB-202, Middlesex, UK), 
K562 (chronic myeloid leukemia) (ATCC: CCL-243, Middlesex, 
UK) and KG-1a (acute mylogenous leukemia)), three human 
lymphoid cell lines (Jurkat (peripheral blood T cell leukemia) 
(ATCC: TIB-152, Middlesex, UK), MOLT-3 (acute lymphoblastic 
leukemia patient released following chemotherapy) (ATCC: CRL-
1552, Middlesex, UK), and CCRF-CEM (acute lymphoblastic 
leukemia) (ATCC: CCL-119, Middlesex, UK)) and one histocytic 
lymphoma cell line (U937) (ATCC: CRL-1593.2, Middlesex, UK) 
together with the non-tumor cord blood (CD34+) cells (Stem cell 
Technologies, Grenoble, France), were used in this study. All 
leukemia cell lines except MOLT-3 are p53-deficient, being either 
null, or containing mutant p53 [22-24]. MOLT-3 cells express wild 
type p53 [25], but are mutant for PTEN [26]. All cells were tested 
for mycoplasma contamination using the MycoAlert TM 
mycoplasma detection kit (Lonza Walkersville, Inc) and were all 
tested negative throughout the study.  
2.2. Culture Conditions 
 Two million cells per milliliter were seeded in T75cm? flasks 
(Invitrogen, Paisley, UK) in RPMI 1640 medium (Invitrogen, 
Paisley, UK) supplemented with 10% (v/v) fetal bovine serum, 
1.5mM L-Glutamine and 100 ?g/ml penicillin/streptomycin 
(complete RPMI) and incubated at 37ºC with 5% CO2.  
2.3. CellTiter-Glo
®
 Luminescent Cell Viability Assay 
 The CellTiter-Glo® Luminescent Cell Viability Assay Kit 
(Promega, Southampton, UK) was used as a homogeneous method 
to determine the number of viable cells in culture was based on a 
quantification of ATP levels. This assay was used to determine the 
effect of each polyphenols on cellular proliferation in each of the 
cell lines. Cells were seeded into white 96-well plates (Fisher 
Scientific, Loughborough, UK) at 2.5 x 103 cells per well and 
treated with each polyphenol dissolved in ethanol: quercetin, 
apigenin, chrysin, emodin, aloe-emodin, rhein, cis-stilbene and 
trans-stilbene (Sigma, Poole, UK) at concentrations between 2 - 
500 ?M for 24, 48 and 72 h together with ethanol vehicle controls 
at 0.1 % (v/v) ethanol. All treatments were performed in triplicate, 
in three independent experiments. Following treatments, cellular 
proliferation was measured as per manufacturer’s instructions. The 
IC50 was determined for each polyphenol in each cell line. This was 
defined as the treatment concentration at which 50% reduction in 
cellular proliferation was observed. This was calculated from a 
linear regression equation of each standard curve for each 
polyphenol with each cell line. The IC25 was also determined in 
order to provide treatment ranges for apoptosis detection, and cell 
cycle treatments, but were not used to determine the effectiveness 
of treatments.  
2.4. Cell Cycle Analysis using Propidium Iodide (PI) and Flow 
Cytometry 
 The effect of polyphenols on the progression of the cell cycle 
was studied using flow cytometric analysis using Propidium Iodide 
(PI) stain. Propidium Iodide emits red fluorescence when 
intercalated with double stranded nucleic acids. It can be used to 
quantify the proportion of cells in each phase of cell cycle (G0/G1, S 
and G2/M); and determine whether cells are accumulated in a 
specific phase. For cell cycle analysis, cells were seeded in 12 well 
plates at 0.5 x 106 cells per well and treated for 24 h with the IC50 
concentrations of each polyphenol determined by CellTiter-Glo® 
assay. Following treatment cells were harvested and centrifuged at 
400 g for 5 min. The supernatant was removed, and cells were 
washed twice in 100 ?l cold PBS. Cells were fixed by adding 100 ?l of 80% ethanol/H2O (v/v) and stored overnight at -20°C. Then, 
cells were washed twice with cold PBS prior to addition of 300 ?l 
of 50 ?g/mL PI (Sigma, Poole UK) and 50 ?l of 0.1 unit/mL RNase 
(Sigma, Poole UK). Samples were PI stained overnight at 4ºC and 
analyzed on the flow cytometer with BD FACS Calibur instrument. 
Ten thousand events were acquired per sample and the DNA 
histogram of cell cycle phase was analyzed with FlowJo software 
using the Waston (pragmatic) equation (Tree Star, Ashland, OR, 
USA). 
Table 1. The chemical structure and classification of each selected 
polyphenols.  
Classification and Polyphenols Chemical Structure 
Flavonoid (Quercetin), Anthraquinone (Emodin) 
 
 
Flavonoid (Apigenin) Anthraquinone (Aloe-emodin) 
 
 
Flavonoid (Chrysin) Anthraquinone (Rhein) 
 
 
Stilbene (Cis-stilbene) Stilbene (Trans-stilbene) 
 
 
This table shows the chemical structure of the flavonoids: flavonol (quercetin) and 
flavones (apigenin and chrysin); the anthraquinones (emodin, aloe-emodin and rhein); 
plus the two stilbene isomers (cis-stilbene and trans-stilbene). 
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2.5. Apoptotic Analysis 
 Cells were seeded in 12 well plates 0.5 x 106 cells per well and 
treated for 24 h with dose ranges between IC25 and IC50 for each 
polyphenol as determined from the CellTiter-Glo®. Apoptosis was 
assessed using the NucView caspase 3 activity assay (Cambridge 
Bioscience, Cambridge, UK) and morphological assessment of 
Hoescht 33342 stained cells (Sigma, Poole, UK).  
2.5.1. NucView Caspase 3 Activity Assay by Flow Cytometry 
 The NucView caspase 3 activity assay is a novel cell membrane 
permeable fluorogenic caspase substrate designed for detecting 
caspase 3 activity; which is believed to play a key role in the 
initiation of cellular events during early apoptosis. Using this 
method, it was possible to determine the AP50 concentrations for 
each polyphenol in each leukemic cell line. This was defined as the 
treatment concentration at which 50% of treated cells had 
undergone apoptosis. Following treatments, 200 ?l of each cell 
suspension was transferred to a flow cytometry tube and 5 ?l of 
caspase 3 activity assay (0.2 mM) (Promega, Southampton, UK) 
was added. This was incubated for 10 min in the dark, and then 
each sample was analyzed on the flow cytometer using a BD FACS 
Calibur instrument (BD, Oxford, UK). Ten thousand events were 
acquired per sample and the data was analyzed using Flow Jo 
software (Tree Star, Ashland, OR, USA). 
2.5.2. Hoechst 33342 Nuclear Morphological Analysis by 
Fluorescence Microscopy 
 Apoptotic cells and nuclear morphology was assessed by 
fluorescence microscopy following Hoechst 33342 nucleic acid 
staining. Following polyphenol treatments, cells from each culture 
well was transferred to eppendorf tubes and centrifuged for 5 min at 
400 g at 4ºC. The supernatant was removed, and cells washed in 
100 ?l PBS. The cells were fixed in 4% (w/v) paraformaldhyde/ 
PBS and cytospins formed (Shandon Cytospin 3 Centrifuge, Thermo, 
US). Samples were air dried and then stained in 50 ?l of 10 μg/ml 
Hoescht 33342 staining (Sigma, Poole, UK) for 10 min in the dark. 
Slides were mounted in immersion oil and examined using a 
fluorescence microscope (Olympus, BX60, UK). Two hundred cells 
(live and apoptotic) were counted and the percentage of apoptotic 
nuclei determined for each sample. Images were captured using 
LabWorks 4.0 (UVP BioImaging Systems, Loughborough, UK).  
2.6. Statistical Analysis 
 The means and standard deviations (STD) were calculated. Stats 
Direct software (Stats Direct Ltd, England) was used to test whether 
data followed a normal distribution using a Shapiro Wilke test. Data 
which did not follow a normal distribution, was transformed using 
the logit transformation and statistically analyzed using one way 
ANOVA and Tukey post hoc tests to investigate significant differences. 
Results were considered statistically significant when P ? 0.05. 
3. RESULTS 
3.1. Effects of Polyphenol Treatments on Cell Proliferation in 
Leukemia Cell Lines 
 Treatment with polyphenols for 24 h resulted in reduced cell 
proliferation in all 8 leukemia cell lines to a greater extent than in 
non-tumor cells (Fig. 1 and Tables 2, 3). Using the lowest dose of 
polyphenols at which there was a significant inhibition on cellular 
proliferation (Table 2) and IC50 values (Table 3); it was possible to 
rank the polyphenols in order of effectiveness. The most effective 
polyphenols at significantly reducing cell proliferation compared to 
vehicle controls (p<0.05) were emodin, quercetin, and cis-stilbene 
(Fig. 1 and Table 2). A more moderate affect was shown by 
apigenin and rhein; and the least effective polyphenols were aloe-
emodin, trans-stilbene and chrysin. Both lymphoid and myeloid 
leukemia cell lines were sensitive to emodin, quercetin, and cis-
stilbene treatment (Fig. 1 and Table 2). However, it is important to 
note that each leukemia cell line demonstrated differing sensitivity 
with the remaining polyphenols. Generally, the lymphoid cell lines 
were usually more sensitive to polyphenol treatment than myeloid 
cell lines (Fig. 1 and Tables 2, 3).  
 Emodin consistently gave the lowest IC50 values (5-22 μM) 
(Table 3), showing a significant effect on cellular proliferation of 
all leukemia cell lines, with a slightly greater effect on lymphoid 
than myeloid cells. Emodin also significantly reduced proliferation 
in the non-tumor cells (p<0.05). However, the IC50 in the non-
tumor cells (~150 μM) was much greater than that seen for all the 
leukemia cells, demonstrating selectivity towards leukemia cell 
lines (Fig. 1 and Tables 2, 3). Similarly, quercetin had a more 
potent effect on lymphoid cell line (IC50 value 8-20 μM) than 
myeloid cell lines (IC50 33-155 μM). The least sensitive leukemia 
cell line to quercetin treatment with an IC50 of 155 μM was the 
acute myelogenous leukemia KG-1a cell line (Fig. 1 and Table 3). 
However the human promyelocytic leukemia (HL-60) cell line had 
a much lower IC50 value (8 μM), which was similar to those values 
seen in lymphoid cells (Fig. 1 and Table 3). Cis-stilbene 
demonstrated IC50 values of 25-85 μM (Fig. 1 and Tables 2, 3) and 
affected both lymphoid and myeloid cells equally (Fig. 1).  
 Apigenin and rhein had a moderate effect on cellular 
proliferation. Apigenin demonstrated a greater effect on the 
lymphoid cells (IC50 140-195 μM) compared to the myeloid cells 
(IC50 100-500 μM) (Fig. 1 and Table 3). Rhein demonstrated a 
significant decrease in cellular proliferation of all leukemia cell 
lines and the non-tumor cells (p<0.05), with a similar effect seen in 
both lymphoid and myeloid cell lines (Fig. 1 and Tables 2, 3).  
 Aloe-emodin, chrysin and trans-stilbene were the least effective 
polyphenols on cellular proliferation. Aloe-emodin had IC50 values 
between 180-450 μM; more than ten times higher than emodin. 
Aloe-emodin, like emodin, showed a greater effect on lymphoid 
cell lines than myeloid cell lines (Fig. 1 and Tables 2, 3). Similarly, 
chrysin demonstrated comparatively high IC50 values, and again 
was more effective on lymphoid cells (IC50 chrysin 128-217 μM) 
compared to the myeloid cells (IC50 335-500 μM respectively) (Fig. 
1 and Table 3). Trans-stilbene had some of the highest IC50 values 
ranging between 109-500 μM. These were much higher than those 
values found with its isomer, cis-stilbene (Fig. 1 and Tables 2, 3). 
Despite the differing effects on the leukemia cells, trans-stilbene 
did not affect the cellular proliferation of the non-tumor cells, until 
the treatment dose reached 500 μM (Fig. 1).  
3.2. Cell Cycle Accumulation Following Polyphenol Treatments 
in Leukemia Cells 
 Treatment of leukemic cell lines at the IC50 as determined by 
CellTiter-Glo® assay of each polyphenol for 24 h significantly 
induced cell cycle arrest in all leukemia cell lines (p<0.05) (Table 4). 
There was however no significant arrest in cell cycle in the non-
tumor progenitor cells (CD34+) within the IC50 treatment ranges 
used for leukemic cell lines (Table 4). The phase of cell cycle 
accumulation varied according to polyphenol treatment and cell  
line (Table 4). For example, Jurkat cells demonstrated cell cycle 
accumulation in S-phase following quercetin, apigenin, rhein, aloe-
emodin and trans-stilbene treatments (p<0.05) (Fig. 2, Table 4), 
whilst cells accumulated in G0/G1 phase following chrysin, emodin 
and cis-stilbene treatment (p<0.05) (Fig. 2 and Table 4). A more 
consistent effect was seen following emodin treatment, which 
accumulated the cells at G0/G1 phase in all leukemia cell lines. 
Similarly cis-stilbene and chrysin also induced cells accumulation 
at G0/G1 phase in 7 out of the 8 leukemia cell lines (Table 4). 
Generally, polyphenols appeared to cause G0/G1 phase accumulation 
in most of leukemic cell lines (Table 4).  
3.3. Induction of Apoptosis Following Polyphenol Treatments in 
Leukemia Cells 
 All eight polyphenols induced significantly higher levels of 
apoptosis determined by caspase 3 activity in all leukemia cell lines 
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Fig. (1). Effect of eight polyphenols (quercetin, apigenin, chrysin, rhein, emodin, aloe-emodin, cis-stilbene and trans-stilbene) on cellular proliferation of three 
lymphoid leukemia (CCRF-CEM, MOLT-3, JURKAT; red lines), one histocytic lymphoma (U937; orange lines), four human myeloid leukemia cell lines 
(K562, HL-60, KG-1a , THP-1; blue lines), and one non-tumor normal progenitor cells (CD34+; black line). This was evaluated by CellTiter-Glo® assay. Cells 
were treated with 0, 2, 10, 50, 250 ?M of quercetin, emodin, cis-stilbene; and with 0, 2, 10, 50, 250, 500 ?M of apigenin, chrysin, rhein, aloe-emodin, trans-
stilbene for 24 h. Data was normalized to the vehicle control which was assigned 100% cell viability. The data is expressed as mean ± STD (three independent 
experiments, each in triplicate). The statistical significance was determined by comparison with the vehicle control, statistical significance was set at p<0.05 
and determined by one way ANOVA and Tukey post-hoc test. Statistical results are summarised in Table 2 which shows the lowest dose that induced 
significant inhibition compared to vehicle control. All concentrations above these points were also statistically significant. The IC50 for each polyphenol in each 
cell line were determined and shown in Table 3. 
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Table 2. The lowest dose of polyphenols that induced a significant decrease in cellular proliferation compared to the vehicle controls, p<0.05. 
Polyphenol treatments were: 0, 2, 10, 50, 250, 500 ?M for 24 h.  
The lowest dose of polyphenols (?M) at which there was a significant inhibition of  
cell proliferation compared to the vehicle control. Cell Types 
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin Cis- Stilbene Trans-Stilbene 
JURKAT 2  50  50  50  2  50  2  50  
CCRF-CEM 2  10  50  50  2  50  10  50  
L
y
m
p
h
o
id
 
le
u
k
a
em
ia
 
MOLT-3 2  50  50  50  2  50  2  50  
HL60 2  10  50  50  2  50  2  50  
THP-1 2  10  250  50  2  250  2  250  
K562 2  10  250  50  2  50  2  50  M
y
el
o
id
  
le
u
k
a
em
ia
 
KG1a 10  10  250  50  2  50  2  50  
C
el
l 
li
n
es
 
H
is
to
cy
ti
c 
ly
m
p
h
o
m
a
 
U937 2  10  50  50  2  50  2  50  
P
er
ip
h
er
a
l 
b
lo
o
d
 c
el
ls
 
N
o
n
-t
u
m
o
u
r 
co
n
tr
o
l 
ce
ll
s 
CD34+ 250  500  500  250  50  500  250  250  
The polyphenols were ranked in order of activity with respect to significant reduction of cellular proliferation in lymphoid cells (emodin = quercetin > cis-stilbene > apigenin > rhein 
= trans-stilbene = aloe-emodin = chrysin); and in myeloid cells (emodin = cis-stilbene ? quercetin > apigenin > rhein > aloe-emodin = trans-stilbene > chrysin). Note that the 
treatment doses that caused significant inhibition of cellular proliferation in all leukemic cell lines were much lower than in the non-tumor cells (CD34+). Due to the wide range of 
concentrations used and the number of cell lines investigated, it was not possible to indicate significance levels on Fig. (1), and thus, Table 2 indicates the lowest dose of polyphenol 
at which significance was obtained for each cell line, providing the statistical analysis for Fig. (1). 
 
Table 3. The IC50 values responsible for 50% inhibition of cellular proliferation in each leukemic and non-tumor control cell line following 24 h 
treatment with each polyphenols.  
Polyphenols IC50 in ?M 
Cell Types 
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin Cis- Stilbene Trans-Stilbene 
JURKAT 10  143  180  277  9  185  38  163  
CCRF-CEM 10  195  128  140  22  211  53  109  
L
y
m
p
h
o
id
 
le
u
k
a
em
ia
 
MOLT-3 20  140  217  158  8  220  25  180  
HL60 8  100  328  150  5  225  32  135  
THP-1 37  180  500  158  10  450  45  380  
K562 33  350  340  380  13  309  53  500  M
y
el
o
id
 
 l
eu
k
a
em
ia
 
KG1a 155  500  335  169  15  310  85  250  
C
el
l 
li
n
es
 
H
is
to
cy
ti
c  
ly
m
p
h
o
m
a
 
U937 8  160  217 135  7  250  30  340  
P
er
ip
h
er
a
l 
b
lo
o
d
 c
el
ls
 
N
o
n
-t
u
m
o
u
r 
co
n
tr
o
l 
ce
ll
s 
CD34+ >500  >500  >500  380  150  >500  >500  500  
This was determined by CellTiter-Glo® Luminescent assay. The polyphenols were ranked in order of activity with respect to inhibition of 50% proliferation in lymphoid cells (emodin 
= quercetin > cis-stilbene > apigenin > trans-stilbene ? chrysin = rhein > aloe-emodin); and in myeloid cells (emodin = cis-stilbene ? quercetin > apigenin = rhein > aloe-emodin = 
trans-stilbene = chrysin). In Non-tumour cells (CD34+), did not reach 50% inhibition until the polyphenol treatments excessed 500?M, the only exceptions were emodin and rhein. 
Note that the highest doses of aloe-emodin, chrysin, rhein and trans-stilbene would be clinically impractical, while quercetin emodin, cis-stilbene had much lower doses and thus are 
potentially more clinically useful. 
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Table 4. The effect of polyphenol treatment on the cell cycle progression in myeloid and lymphoid cell lines.  
Percentage of 
cells in all phases 
of cell cycle 
The percentage of cells in the phases of cell cycle at which there was a significant accumulation of  
cells when compared to vehicle controls after treatment with IC50 dose of each polyphenol following 24h. Cell lines 
Vehicle Control Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin Cis- Stilbene Trans-Stilbene 
JURKAT 
G0/G1 = 52.13% 
S = 36.06% 
G2/M = 10.01% 
S = 51% S = 49% G0/G1 = 65% S = 45.70% G0/G1 = 60% S = 49% G0/G1 =65% S = 47% 
CCRF-
CEM 
G0/G1 = 41.9% 
S = 47.2% 
G2/M = 7.8% 
S = 51.4% G0/G1 =52.2% G0/G1 =49.4% G0/G1 =54% G0/G1 =50% G0/G1 =49% G0/G1 =51.1% G0/G1 =49.1% 
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MOLT-3 
G0/G1 = 64.5% 
S = 24.8% 
G2/M = 7.5% 
G2/M =19% S =35% G0/G1 =69.3% G0/G1=72% G0/G1 =70% G0/G1 = 68% G2/M = 15% G0/G1 = 69% 
HL60 
G0/G1 = 56.8% 
S = 33.6% 
G2/M = 8.45% 
G0/G1 =66.2% G0/G1=67% S =45.5% G0/G1=65% G0/G1 =67.7% S =35% G0/G1 =70.9% S =41.9% 
THP-1 
G0/G1 = 42.3% 
S = 31.1% 
G2/M = 26.4% 
G0/G1 =52% G2/M =32% G0/G1 =52.1% G0/G1 =47% G0/G1= 50.8% G0/G1 =52% G0/G1=50% G0/G1 =53% 
K562 
G0/G1 = 53.7% 
S = 32.06% 
G2/M = 13.6% 
G0/G1=60% S =50.2% G0/G1 =59% S =48%% G0/G1 =66% G2/M =20% G0/G1 =64% G2/M =24.5% 
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KG1a 
G0/G1 = 44.6% 
S = 34.6% 
G2/M = 18.7% 
G0/G1=52% S = 50% G0/G1 =50% G0/G1 =49% G0/G1 =52.9% G0/G1 =50% G0/G1 =51% G2/M =23.7% 
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U937 
G0/G1 = 44.03% 
S = 40.1% 
G2/M = 19.1% 
G2/M =25% G0/G1 =59% G0/G1 =70% G0/G1 =55% G0/G1 =60% G0/G1 =53% G0/G1 =64% G0/G1 =62% 
N
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l 
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CD34+ 
G0/G1 = 53% 
S = 25.8% 
G2/M = 20.7% 
No Arrest 
<50?M 
No Arrest 
?250?M 
No Arrest 
<250?M 
No Arrest 
<50?M 
No Arrest 
<50?M 
No Arrest 
<500?M 
No Arrest 
?250?M 
No Arrest 
?500?M 
The cell cycle phase was assessed by flow cytometric analysis of propidium iodide (PI) stained cells, and the percentage of cells accumulation in each phase of cell cycle (G0/G1, S, 
G2/M) was determined from the DNA histograms of each sample analysing by FlowJo software using Waston (pragmatic) equation. The data shows the phases of cell cycle in which 
each cell type was significantly accumulated when compared with the vehicle control, when treated for 24 h with IC50 concentration for each polyphenol, as determined by CellTiter-
Glo® assay (p<0.05). The table shows the percentage of cells in each phases of cell cycle at which there was a significant accumulation. No significant arrest in cell cycle was 
observed in the non-tumor progenitor cells (CD34+) within the IC50 ranges used to treat the leukemic cell lines. 
 
compared to the non-tumour cells (p<0.05) (Fig. 3 and Table 5). 
Emodin, quercetin, cis-stilbene and apigenin were the most 
effective polyphenols at inducing apoptosis with AP50 values 
ranging between 2-27 μM, 19-50 μM, 8-50 μM, 35-150 μM, 
respectively, in all leukemia cell lines (Table 6). The leukemia cell 
lines demonstrated differing sensitivity to the polyphenols; Jurkat 
lymphoid cells were most greatly affected, whilst THP-1 myeloid 
cells were the least affected to all polyphenols treatments (Fig. 3).  
 Quercetin, apigenin, emodin, aloe-emodin and chrysin 
demonstrated a greater toxicity towards lymphoid leukemia cell 
lines than myeloid leukemia cell lines (Fig. 3 and Tables 5, 6). In 
contrast, rhein, cis-stilbene and trans-stilbene demonstrated similar 
sensitivity to both myeloid and lymphoid cell lines. Some cell lines 
were more resistant to polyphenol treatment. The THP-1 myeloid 
cell line was only sensitive to emodin, rhein and apigenin treatment 
(Fig. 3 and Tables 5, 6); whilst the myeloid cell lines (K562 and 
KG-1a) were only sensitive to apigenin treatment (Fig. 3 and Table 6).  
 Morphological assessment of apoptosis by Hoechst 33342 
staining confirmed the patterns of apoptosis induction seen in 
caspase 3 activity assays, although the AP50 values determined 
using this method were higher demonstrating that the progression to 
the later stages of apoptosis required a greater treatment dose (Fig. 
4 and Table 6).  
4. DISCUSSION 
 Over the past 10 years, researchers have confirmed that dietary 
polyphenols are capable of inhibiting cell proliferation, inducing 
cell cycle arrest and apoptosis in a number of solid tumor cell lines 
[11-16], however there has not been a direct comparison of the 
effect of polyphenols on leukemia cell lines and non-tumor cells. 
Here, we directly compared the effect of eight polyphenols 
(quercetin, apigenin, chrysin, rhein, emodin, aloe-emodin, cis-
stilbene and trans-stilbene) on four lymphoid and three myeloid 
leukemia cell lines; one histocytic leukemia cell line; and the non-
tumor blood progenitor cells (CD34+). The effects of these 
polyphenols were shown to be greater in leukemia cells compared 
to non-tumor blood progenitor cells (CD34+). When non-tumor 
cells were treated with quercetin and cis–stilbene, chrysin, apigenin 
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and aloe-emodin, there were no significant decrease on cellular 
proliferation until the treatment concentration increased to 250-500 ?M. There was a significant decrease on proliferation of non-tumor 
cells when treated with ?250 ?M of emodin, rhein and trans-
stilbene; however this is 5-10 times higher than the IC50 values 
reported for all leukemia cells (Fig. 1 and Tables 2, 3). Consequently, 
we have shown that each of the polyphenols caused a decrease in 
proliferation in all leukemia cell lines and can be ranked according 
to their effectiveness: emodin > quercetin > cis-stilbene > apigenin ? rhein > aloe-emodin ? trans-stilbene ? chrysin. However, it is 
important to note that this ranking did vary between individual cell 
lines (Table 3).  
 Emodin was the most effective polyphenol at reducing cellular 
proliferation. It was by far the most effective of the anthraquinones 
investigated. The structural differences between the anthraquinones 
are slight and, indeed, emodin and aloe-emodin have the same 
structural formula (C15H10O5), although the orientations of the 
functional groups vary. The IC50 values for emodin (5-22 ?M) were 
the lowest of all the studied polyphenols; and were comparable with 
those previously reported in squamous cell carcinoma (SCC-4) cells 
[27]. Emodin was shown to consistently induce accumulation of 
cells at G0/G1 phase in all leukemia cell lines, and induced 50% 
apoptosis in 5 of the 8 leukemia cell lines (Jurkat, MOLT3, HL-60, 
THP-1 and U937). This is consistent with previous studies in which 
emodin induced apoptosis in HL-60 [28] and SCC-4 [27] cells. 
 Quercetin was also a potent polyphenol, with IC50 value ranging 
between 8-33 ?M and induction of apoptosis with AP50 value 
ranging between 19-50 ?M. Quercetin was the most effective of the 
flavonoids tested and was routinely 5-10 times more potent than 
apigenin and chrysin. The IC50 values noted are at the lower end of 
values previously reported (20-278? ?M), in breast (MDA-MB-231 
and MDA-MB-453 [29, 30], MCF-7 [31]), cervical (HeLa) [32-34], 
liver (HepG2) [35], lung (A-549) [36] and leukemia cell lines (HL-
60 and K562) [17, 37]. Lymphoid cell lines were more susceptible 
to quercetin treatment than myeloid leukemia cells. The only 
exception being the promyelocytic leukemia cells (HL-60), which 
 
Fig. (2). An example of the cell cycle phases (G0/G1, S, G2/M) for the acute T cell leukemia (Jurkat) cells after treatment with IC50 concentration of each 
polyphenol following 24 h as determined by CellTiter-Glo® assay. The percentage of cells in each phase was analyzed with Flow Jo software using Watson 
pragmatic model. Each polyphenol caused a significant accumulation of cells in cell cycle comparing to the vehicle control. Quercetin, apigenin, trans-stilbene 
and aloe-emodin and rhein significantly induced accumulation in S-phase (p<0.01), in contrast emodin, cis-stilbene and chrysin significantly induced 
accumulation in G0/G1 phase (p<0.01). 
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Fig. (3). Effect of eight polyphenols (quercetin, apigenin, chrysin, rhein, emodin, aloe-emodin, two cis-stilbene and trans-stilbene) on apoptosis of three 
lymphoid leukemia (CCRF-CEM, MOLT-3, and JURKAT; red lines), one histocytic lymphoma (U937; orange lines), four human myeloid leukemia cell lines 
(K562, HL-60, KG-1a , THP-1; blue lines) and the non-tumor normal progenitor cells (CD34+; black line). Apoptosis was assessed using a caspase 3 activity 
assay and analyzed by flow cytometry. Cells were treated with range of concentrations for each polyphenol for 24 h and the range of IC25 and IC50 as 
determined by CellTiter-Glo® assay. The treatment concentrations for emodin were 0, 0.4, 2, 10, 50 ?M, for quercetin and cis-stilbene were 0, 2, 10, 50 ?M; 
and for apigenin, chrysin, aloe-emodin, rhein and trans-stilbene were 0, 10, 50, 250 ?M. All data was normalized to the vehicle-only control, which was 
assigned a 0% apoptotic level. The data is expressed as mean ± STD (three independent experiments, each in triplicate). The statistical significance was 
determined by comparison with the vehicle control, statistical significant was set at p<0.05 and determined by one way ANOVA and Tukey post-hoc test. 
Statistical results are summarised in Table 5 which shows the lowest dose that induced significant inhibition compared to vehicle control. All concentrations 
above these points were also significant. The AP50 for each polyphenol in each cell line were determined and shown in Table 6. 
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Table 5. The lowest dose of polyphenols which induced significant induction of caspase 3 activity, compared to the control (p<0.05).  
The lowest dose of polyphenols (?M) at which there was a significant induction of apoptosis compared to the vehicle control. 
Cell Types  
Quercetin Apigenin Chrysin Rhein Emodin Aloe - Emodin Cis- Stilbene Trans-Stilbene 
JURKAT 2  50  50  50  2  50  10  50  
CCRF-CEM 2  10  50  50  10  50  50  50 
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MOLT-3 10  50  50  50  2  50  10  50  
HL60 10  50  50  50  10  50  10  50  
THP-1 10  10  250  50  2  50  50  250  
K562 10  10  250  50  2  50  50  50  M
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KG1a 10  10  250  50  2  50  10  50  
C
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U937 2  50  50  50  2  50  2  50  
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CD34+ 50  250  250  50  10  250  250  250  
Apoptosis was assessed by caspase 3 activity assay. The polyphenols were ranked in order of activity with respect to significant induction of apoptosis in lymphoid cells (emodin = 
quercetin ? cis-stilbene > apigenin > rhein = trans-stilbene = aloe-emodin = chrysin); and in myeloid cells (emodin > quercetin > cis-stilbene = apigenin > rhein = aloe-emodin ? 
trans-stilbene > chrysin). Note that the treatment doses which caused significant induction of apoptosis in all leukemic cell lines were much lower than of the non-tumor cells 
(CD34+). Due to the wide range of concentrations used and the cell lines investigated, it was not possible to indicate significance levels on Fig. (3) and thus Table 5 provides the 
lowest doses of polyphenol at which significance was obtained. 
 
Table 6. The AP50 values responsible for 50% induction of apoptosis, determined by: Caspase 3 activity assay (C3) and Hoechst 33342 staining 
(Hoe).  
Polyphenols AP50 in ?M 
Quercetin Apigenin Chrysin Rhein Emodin 
Aloe - 
Emodin 
Cis- Stilbene 
Trans-
Stilbene 
Cell Types 
C3 Hoe C3 Hoe C3 Hoe C3 Hoe C3 Hoe C3 Hoe C3 Hoe C3 Hoe 
JURKAT 19 25 35 90 40 30 >250 >500 2 9 50 130 31 50 250 310 
CCRF-
CEM 
50 50 50 100 250 40 200 250 >10 >500 50 150 >50 >500 >500 200 
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MOLT-3 50 50 50 125 140 38 200 265 5 9 50 150 44 50 350 400 
HL60 50 50 84 129 175 75 >250 >500 8.5 6 185 190 31 49 40 50 
THP-1 >50 >500 110 220 >250 >500 50 60 7.8 10 >250 283 >50 >500 >500 >500 
K562 >50 205 150 190 >250 >500 >250 >500 >10 >500 >250 500 >50 410 >500 460 M
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KG1a >50 125 89 235 >250 >500 >250 >500 >10 >500 >250 360 >50 350 >500 360 
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U937 50 50 45 130 150 32 60 140 4 27 50 195 8 20 200 225 
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CD34+ >50 >500 >250 >500 >250 >500 >250 >500 >10 >500 >250 >500 >50 >500 >500 >500 
The polyphenol were ranked in order of induction of 50% apoptosis in lymphoid cells (quercetin ? emodin = cis-stilbene > apigenin > aloe-emodin > chrysin ? rhein > trans-stilbene). 
The HL-60 human promyelocytic leukemia cell line was the only myeloid cell to reach an AP50. The non-tumour cells (CD34+) did not reach 50% apoptosis with any of the treatment 
doses investigated. THP-1, K562 and KG-1a myeloid cell lines were the most resistant cell lines, although did they reached an AP50 with apigenin treatment. 
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Fig. (4). A typical example of morphological assessment of apoptosis using Hoechst 33342 nuclear staining, after treatment with the IC50 concentration for each 
polyphenol for 24 h: (A) Shows the Jurkat lymphoid leukemia cells, which were one of the most sensitive cell lines to polyphenol treatment and (B) Shows 
THP-1 myeloid leukemia cells, which were one of the most resistant cell lines to polyphenol treatment. Apoptotic cells were identified by their irregular shape, 
intensely stained nuclei, cell shrinkage, blebbing and chromatin condensation and the formation of apoptotic bodies. Scale bar = 100 ?m. Arrow indicates 
examples of apoptotic cells. 
 
showed the same level of sensitivity as lymphoid cells. Quercetin 
demonstrated a differential induction of apoptosis in each leukemia 
cell line although the AP50 values were consistently low. Previously, 
quercetin has been reported to induce apoptosis in a range of solid 
tumors, via a caspase 3-dependent mechanism [29, 31 38], and in 
HL-60 cells via decreased PI3K/AKT pathway activity [39]. 
However, there are no reported AP50 values for these studies. 
Quercetin was found to have a differential effect on the cell cycle in 
myeloid and lymphoid cell lines. Inducing accumulation of cells at 
G0/G1 phase in all myeloid cell lines, and either S-phase (Jurkat and 
CCRF-CEM) or G2/M phase (U937 and MOLT3) accumulation in 
the lymphoid cell lines (Table 4). This varied effect of quercetin has 
been previously observed, where it induced accumulation in S-
phase in breast cancer (MCF-7) [31] and in G2/M phase in cervical 
cancer (HeLa) cell lines [32, 33]. Together with our study, this 
suggests that quercetin causes differential effects on cell cycle 
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dependant on cell type, even in comparatively similar leukemia cell 
lines. This may reflect expression of different molecular target in 
myeloid and lymphoid cell lines; or a differential effect on the same 
pathway in different cell lineages.  
 Cis-stilbene was much more effective than its isomer trans-
stilbene in all leukemia cell lines. This is reflected in IC50 values for 
cis-stilbene (25-85 ?M) and trans-stilbene (109-500 ?M); however, 
these values were considerably higher than those previously 
reported in solid tumors [40, 41]. Very few studies have 
investigated the effects of stilbenoids on cell cycle. Cis-stilbene has 
been reported to induce cells accumulation in G2/M phase in the 
lung cancer cell line (A549) [42], and in S-phase in one leukemia 
cell line (HL-60) [19]. Our results have shown that cis-stilbene 
consistently caused cell accumulation at G0/G1 phase in 7 of the 8 
cell lines including the HL-60 cell line. This contrasts with the 
finding that HL-60 cells when treated with the stilbene derivate 3, 
3', 4, 4', 5, 5'-hexahydroxystilbene induced S-phase accumulation 
[19]. A less consistent effect was found with trans-stilbene 
treatment, which caused cell accumulation at different phases of 
cell cycle in all leukemia cell lines. Both cis- and trans-stilbene 
induced caspase-3 activity of early apoptosis and morphological 
changes characteristic of late apoptosis in the majority of leukemia 
cell lines. Cis-stilbene was able to induce apoptosis in three 
lymphoid cell lines (Jurkat, MOLT3, and U937) with AP50 values 
ranging between 20-50 ?M, the remaining cell lines were more 
resistant, and did not reach 50% apoptosis even when treated with a 
maximal treatment dose (500?M). Similarly, trans-stilbene induced 
apoptosis in the same three lymphoid cell lines, however the AP50 
values were much higher (40-460 ?M), there was also a similar 
resistance to treatment in the remaining lymphoid cell lines. Cis-
stilbene did not show any significant effect on proliferation of the 
non-tumor cells, however, trans-stilbene did, but only at high 
treatment concentration in excess of 250 μM. Previous work has 
shown that stilbenoids can inhibit cell proliferation and induce 
apoptosis in lung (A549) [42, 43], prostate (DU145 and PC3), 
breast (BT-549), colon (HT-29) [40, 41] and one leukemia (HL-60) 
[19, 20] cell line. Trans-stilbene had a reported IC50 values of 25-98 μM at 24 h in two lung cancer cell lines (A549 and CH27) [43]. A 
direct comparison of cis-stilbene and trans-stilbene in lung (A549) 
[42] and leukemia (HL-60) [19] cell lines, demonstrated that cis-
stilbene was more effective than trans-stilbene with IC50 values of 
0.03 μM and 6.25 ?M, respectively, at 24 h [19, 42]. This supports 
the finding of this study that cis-stilbene is more potent than trans-
stilbene in the treatment of leukemia cells. However, the reason for 
this difference is not clear, but may be related to the stability of the 
trans- and cis-isomers in culture. 
 A moderate effect was seen in leukemia cells treated with 
apigenin, with IC50 values between 100-500 ?M. However, in other 
cell types lower IC50 values have been reported, including 36 ?M in 
human cervical cancer cells (HeLa) [44] and 70 ?M in colorectal 
cancer cells (SW480, HT-29 and Caco-2) following 24 h treatments 
[45] suggesting differential activity within tumour types. In 
addition, apigenin induced variable effects on cell cycle, which was 
dependant on the cell lines investigated. This phenomena has also 
been seen in solid tumor cell lines, where apigenin induced G0/G1 
arrest in human cervical cancer (HeLa) cells [44] and G2/M arrest in 
human colon carcinoma (SW480, HT-29 and Caco-2) [45]. 
Apigenin was shown to induce apoptosis in all leukemia cell lines, 
with AP50 values ranging between 35-130 ?M in lymphoid cell 
lines and 84-235 ?M in the myeloid cell lines. In contrast to 
quercetin, apigenin was capable of inducing both an increase in 
caspase 3 indicating early apoptosis, plus morphological evidence 
of late apoptosis, in all leukemia cells lines; including the KG-1a 
and K562 cells which were resistant to emodin, quercetin and cis-
stilbene treatment. This pro-apopotic action of apigenin has been 
previous demonstrated in MDA-MB-453 breast cells [30]. The 
other polyphenols investigated; rhein, chrysin, aloe-emodin 
demonstrated a low potency and thus are unlikely to be of clinical 
use in leukemia treatment. Similar low potency has also been 
shown in solid tumors, for example the reported IC50 for chrysin in 
solid tumor cell lines are between 40 and 100μM [46-48]. 
 Within all the polyphenols agents tested, the leukaemia cells 
were more sensitive than the CD34+ non-tumour cells. 
Interestingly, the proliferation rates and percentages of G0/G1 
population were comparable in all untreated leukaemia and non-
tumour control cells, suggesting sensitivity rates were not related to 
rates of proliferation. The order of sensitivity within the leukaemia 
cells was shown to be dependent on the polyphenol investigated. 
For example, U937 cells were one of the most affected cell lines 
when treated with quercetin, emodin and cis- stilbene, however they 
were the were least affected cell line when treated with apigenin. 
This demonstrates that no single polyphenol is active on all cell 
lines and that specific polyphenols should be selected for each type 
of leukaemia.  
 The cell cycle arrest data showed predominately G0/G1 arrest, 
however some treatments arrested cells in S-phase and G2M. It is 
well known that cell cycle is regulated by the coordinated activity 
of family of protein kinases: cyclin-dependent kinase (CDKs), 
cyclins and CDK inhibitors (CDKIs) [49]. Cell-cycle can be 
arrested via protein kinase inhibitors (CDKIs), such as p21waf1 and 
p27kip1, upon binding to cyclins and CDK complexes and indeed 
modulation of their activities could be possible targets for the 
polyphenols. The stage of cell cycle arrest induced by phenolic 
agents can indicate the molecular mechanisms of action. For 
example it is well known that cells arrested in G1 phase can be via 
inhibition of CDK4 and/or CDK6 [49]. S-phase arrest can be 
caused by inhibition of Cyclin A and Cyclin E through the 
activation of p21 (via p53 in the presence of DNA damage) and p27 
(activated by Transforming Growth Factor of ? (TGF- ?)) [49]. 
Arrest of cells in G2/M phase can be caused by inactivation of 
cyclin B1 with Cdc2 kinase activity through p53 activation [49].  
 Here, we demonstrated that the majority of polyphenols 
investigated induce G0/G1 arrest, suggesting that they may inhibit 
CDK4 and/or -6, however this requires confirmation. Hur, et.al 
(2004) showed that Jurkat cells and T lymphocytes stimulated with 
rosmarinic acid induce p56lck (Lck) protein kinase-dependant 
apoptosis, through the mitochondrial pathway [50]. P56lck is a 
lymphoid-specific protein tyrosine kinase and is usually expressed 
on T lymphocytes [50]. This may explain why the lymphoid cell 
lines were more sensitive than myeloid cell lines. In addition, recent 
investigations showed that polyphenols such as the flavanoids 
(apigenin and quercetin) can act as a p56lck (Lck) protein kinase 
inhibitors [50, 51]. As p56lck is an essential regulator of the cell 
cycle; modulation of this kinase could lead to the G0/G1 arrest. 
However, further investigation is essential to determine the 
molecular mechanisms of each polyphenol. 
 It is well established that tumor suppressor gene p53 has a role 
in the regulation of the cell cycle, as well as in the initiation of 
apoptosis. However the majority of our cell lines were either null or 
mutated for p53, with the exception of MOLT3 which express wild 
type p53 [22-25]. MOLT 3 cells however, display PTEN mutations, 
which results in constitutive activity of AKT [26]. p53 induces Bax, 
which leads to activation of the intrinsic apoptotic pathway. AKT 
promotes pro-apoptotic BAD to be sequestered. Therefore a lack of 
p53 or PTEN both lead to an insensitivity to apoptosis with respect 
to the intrinsic pathway [52]. This suggests that the p53 status does 
not influence the effect of polyphenol treatment in this study. 
 To determine whether the effects of these polyphenols in vitro 
are relevant to their clinical use, it is essential also to consider their 
bioavailability and whether these treatment concentrations are 
achievable in plasma. It has been suggested that physiological 
concentrations of plasma metabolites will not exceed 10 ?M [53-
55]. Our study has shown that quercetin, emodin and cis- stilbene 
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induced significant affects at low doses (between 2 to 10 ?M) 
following 24 h of treatment in most of leukemic cell lines. The data 
available on bioavailability of polyphenols however is still limited, 
but there is evidence that quercetin obtained from plant products 
can result in micromolar concentrations in blood plasma [54, 56], 
supporting the idea that in vivo effects may be possible, through 
diet. However, quercetin has a reported plasma half-life of 11–28 h; 
with a 50-100 mg dose causing a plasma concentration of 0.75–1.5 ?M in plasma [53-56]. This is further complicated as abundant 
dietary polyphenols do not necessarily have the best bioavailability 
profile [53, 55] and they are extensively metabolized by intestinal 
and hepatic enzymes and microflora [53, 57]. The absorption of 
polyphenols depends primarily on their chemical structure, and 
molecular size as well as the degree of glycosylation, esterification, 
and polymerization with other polyphenols [53, 55, 57, 58]. 
 In conclusion, we have shown that the effectiveness of 
polyphenols varied depending on the leukemia cell lineage 
(lymphoid vs. myeloid) and in some cases within the cell lines from 
the same lineage. We have shown that myeloid cell lines (K562 and 
KG-1a) were particularly resistant even to the most active 
polyphenols. This suggests that the molecular mechanism of action 
of the polyphenols may vary in each cell line and this requires 
further investigation. Furthermore, we have demonstrated that 
polyphenols with similar molecular structures such as emodin and 
aloe-emodin, and even cis- and trans-stilbene do not have the same 
effect on leukemia cells. These findings suggest that polyphenols 
have anti-tumor activity against leukemia cells with differential 
effects. The observed differential sensitivity between leukemia and 
normal cells suggests that polyphenols have potential in treatment 
of leukemia. The most potent polyphenols are emodin, quercetin, 
and cis-stilbene; these polyphenols may have potential in treating 
leukemia.  
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